KCM
BIIB icon

Kynam Capital Management’s Biogen BIIB Stock Holding History

Kynam Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,000
Closed -$20M – 34
2022
Q3 		$20M Sell
75,000
-3,951
-5% -$839K 4.22% 8
2022
Q2 		$16.1M Buy
78,951
+40,715
+106% +$8.32M 4.11% 8
2022
Q1 		$8.05M Sell
38,236
-1,764
-4% -$384K 2.61% 12
2021
Q4 		$9.6M Buy
+40,000
New +$10.3M 5.13% 5

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kynam Capital Management's BIIB Position: Q4 2022 in Review

Kynam Capital Management sold out of Biogen (BIIB) in Q4 2022, closing a stake of 75,000 shares — an estimated $20M sold.

Kynam Capital Management first reported a position in BIIB in Q4 2021 and held it in 4 quarters. The position peaked at $20M in Q3 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

  • Kynam Capital Management reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
  • Kynam Capital Management sold 75,000 Biogen shares in Q4 2022, an estimated $20M.
  • Kynam Capital Management first reported a position in Biogen in Q4 2021 and held it in 4 quarters.
  • Kynam Capital Management's Biogen position peaked at $20M in Q3 2022.
  • 1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Kynam Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.